

The Weekly

Sept 30, 2024





DOMESTIC INDICES			
	20-09-2024	27-09-2024	% CHG
SENSEX	84544	85894	1.60
NIFTY	25791	26179	1.50
MIDCAP	60209	60381	0.29
SMALL CAP	19332	19242	-0.47

NIFTY EARNINGS			
NIFTY	FY 23	FY 24E	FY 25E
EPS	807	1000	1130
P/E	23	28	32

SECTORAL INDICES			
	20-09-2024	27-09-2024	% CHG
METAL	31974	34147	6.80
AUTO	59650	61991	3.92
OIL & GAS	30131	31136	3.34
POWER	8492	8773	3.31
REALTY	8616	8825	2.43
TECK	19789	20060	1.37
BANKEKX	60955	61633	1.11
IT	42737	43154	0.98
CG	73374	73620	0.34
HEALTHCARE	44135	44252	0.27
FMCG	23944	23955	0.05
CD	67842	67686	-0.23

GLOBAL INDICES			
	20-09-2024	27-09-2024	% CHG
SHANGHAI	2749	3208	16.70
HANG SENG	18372	20965	14.11
DAX	18720	19474	4.03
CAC	7500	7792	3.89
FTSE	8230	8321	1.11
NASDAQ	17948	18119	0.95
NIKKEI	37724	37964	0.64
S&P 500	5703	5738	0.61
DOW JONES	42063	42313	0.59

INSTITUTIONAL ACTIVITY			
Rs Cr	26-09-2024	27-09-2024	OCT TOTAL
FII	630	-1209	-1209
DII	2405	6887	6887

Indian markets could open lower, in line with mixed Asian markets today and mixed US markets on Sept 27

The U.S. stock market closed mixed Friday, with the Dow Jones Industrial Average finishing at a record peak after investors analyzed fresh data showing inflation continued to cool in August. Major U.S. equities indexes were mixed on the final trading day of the week as investors digested the latest Personal Consumption Expenditure (PCE) data showing consumer price pressures cooled in August, reinforcing expectations that the Federal Reserve will continue cutting interest rates. US stocks gained for a third consecutive week as investors were repeatedly reassured that the economy is cooling without falling off a cliff.

August's personal consumption expenditures price index — the Federal Reserve's favored measure of inflation — increased 0.1%, matching expectations from economists polled by Dow Jones. PCE increased 2.2% at an annualized pace, below the 2.3% forecast. Excluding the volatile food and energy components, the PCE price index increased 0.1% after an unrevised 0.2% rise in July. In the 12 months through August, core inflation advanced 2.7% after climbing 2.6% in July.

The University of Michigan's consumer sentiment index rose to 70.1 in September from 67.9 in August. This month's print beat a Dow Jones estimate of 69.3. The Commerce Department reported a moderate rise in consumer spending while inflation pressures continued to ease. Adjusted for inflation, consumer spending rose 0.1% after climbing 0.4% in July. Economists estimated that the so-called real consumer spending was running at a 3.4% annualized rate so far this quarter. It grew at a 2.8% pace in the second quarter.

Crude oil sold off Thursday on a report that Saudi Arabia is committed to increasing production later this year, even if it results in lower prices for a prolonged period. OPEC+ recently postponed planned output hikes from October to December, but analysts have speculated that the group might delay the hikes again because oil prices are so low.

Investor hopes for a soft landing for the U.S. economy will be put to the test this week, as the government releases closely watched labor market data following a series of disappointing jobs reports. Investors will also watch an address from Fed Chairman Jerome Powell, set to speak on the economic outlook before the National Association for Business Economics on Monday.



Interest rate futures contracts now reflect a 54% chance of a half-point cut in November, versus a still-hefty 46% chance of a quarter-point cut.

China's official manufacturing purchasing managers' index came in at 49.8 in September, compared with 49.1 in August, 49.4 in July and 49.5 in June. The data slightly beat the 49.5 expected among economists polled by Reuters. However, China's Caixin PMI was 49.3, compared to 50.4 in August, according to the private survey compiled by S&P Global. The Caixin data released on Monday indicated that China's manufacturing sector experienced its sharpest contraction in 14 months in September, driven by declining demand and a weakening labor market. The Caixin/S&P Global services purchasing managers' index (PMI) dropped to 50.3 in September from 51.6 in August, the lowest since September 2023.

Japan's benchmark Nikkei 225 index tumbled nearly 5% early Monday after the country's ruling Liberal Democrats chose Shigeru Ishiba, a former defense minister, as the next prime minister. Ishiba has said he supports the Bank of Japan's independence and normalization path in principle, and that the country needs to defeat deflation. Ishida seems to favour normalising interest rates.

Iron ore futures surged in Singapore after the cities of Shanghai, Guangzhou and Shenzhen eased rules on housing purchases, following through on the central government's latest efforts to prop up the embattled property sector. First-tier cities such as Guangzhou lifted all home purchase restrictions over the weekend, while Shanghai and Shenzhen announced plans to ease key buying curbs. China's central bank also said on Sunday it would tell banks to lower mortgage rates for existing home loans before Oct. 31, as part of sweeping policies to support the country's beleaguered property market as the economy slows.

Asia stock markets turned hesitant on Monday as strife in the Middle East offset more stimulus measures in China, while the Nikkei dived on concerns Japan's new prime minister favoured normalising interest rates.

Nifty snapped its six-session winning streak on Sept 27 after hitting its highest level of 26277.35 points. At close, Nifty was down 0.14% or 37.1 points at 26178.9. Nifty stayed in a 126 point range on Sept 27 and formed a small negative candle. After a series of upticks, Nifty seems to have taken a breather. Nifty could now face resistance from the 26250-26475 band on the upside, while 25849 could offer support in the near term.

Welspun Enterprises declared lowest bidder for Rs 1,990 crore Mumbai Water Tunnel Project

The company has been declared the L1 bidder by the Brihanmumbai Municipal Corporation (BMC) for a project worth Rs 1,989.9 crore. The project involves the design and construction of an 8.48 km tertiary treated water conveyance tunnel from the Dharavi WWTF to the Ghatkopar WWTF, to be executed within a period of 93 months.

IDFC FIRST Bank announces completion of IDFC Ltd merger effective Oct 1

IDFC First Bank on Friday announced the completion of merger of IDFC Limited with the bank. This follows the receipt of all requisite shareholder and regulatory approvals, the bank said in a statement. The merger is effective from October 1, 2024, it added. As a result of the merger, it said, 155 equity shares of the bank will be allotted for every 100 equity shares of IDFC Limited held by such shareholder in IDFC Limited as on the Record Date i.e., October 10, 2024. The shares are expected to be credited to shareholders of IDFC Limited on or before October 31, 2024, subject to regulatory processes and clearances, it said.

Punjab National Bank raises Rs 5,000 crore via QIP

Punjab National Bank said that it has raised Rs 5,000 crore through Qualified Institutions Placement (QIP). In a stock exchange filing, the bank said it allotted 48.2 crore shares to Qualified Institutional Buyers at Rs 103.75 per share. Major Institutions include Citigroup, BofA Securities, SBI Contra Fund, Morgan Stanley and Goldman Sachs.



Reliance Infra wins Rs 780 crore arbitration case against Damodar Valley Corp

The Calcutta High Court has upheld a Rs 780 crore arbitration award in favour of Reliance Infrastructure Ltd in a dispute with West Bengal-based Damodar Valley Corporation, the Anil Ambani group firm said in a stock exchange filing. More than a decade back, Reliance Infrastructure had won a contract to set up a 1,200 MW thermal power plant in Purulia in West Bengal for Rs 3,750 crore.

The project was delayed due to disputes and other reasons, leading to DVC seeking damages from Reliance Infrastructure. Reliance Infrastructure, however, challenged this, and an arbitration tribunal in 2019 ruled in favour of the company and directed DVC to pay Rs 896 crore to the company. DVC challenged the order of the arbitral tribunal in the Calcutta High Court, which was dismissed by the court.

Reliance secures Govt's approval for transfer of Viacom18's non-news and current affairs TV channels licenses to Star India

Reliance Industries Limited (RIL) has announced that the Ministry of Information and Broadcasting, Government of India, has approved the transfer of licenses for non-news and current affairs television channels from Viacom18 Media Private Limited to Star India Private Limited subject to conditions laid by Competition Commission of India (CCI).

This decision forms part of the strategic joint venture between Industries Ltd and Disney. Reliance Industries Ltd further stated that the government's approval was granted via an order dated September 27, 2024, following a media release titled "Reliance and Disney Announce Strategic Joint Venture to Bring Together the Most Compelling and Engaging Entertainment Brands in India," first issued on February 28, 2024. It also said this decision builds on previous disclosures made by RIL on August 28, 2024, and August 30, 2024.

Reliance Industries initially disclosed on February 28, 2024, that Viacom18, a subsidiary of the company, would merge with Star India, Disney's Indian unit, to create India's largest television and digital streaming entity. India's competition regulator CCI approved the Rs 70,350-crore merger between Reliance Industries and Disney's Indian media assets on August 28, 2024, with the Mumbai bench of the National Company Law Tribunal (NCLT) granting clearance for the Viacom18-Star India deal on August 30.

Vodafone Idea seals Rs 13,500 crore equipment deal with Nokia

Vodafone Idea has signed a Rs 13,500 crore deal with Nokia for 4G and 5G network equipment over three years. Nokia will supply gear for nine circles, while Vi negotiates with Ericsson and Samsung for other regions. This move aims to enhance Vi's market competitiveness against Reliance Jio and Bharti Airtel.

India to boost crude oil refining capacity by 35-40 MT by Fiscal 2030

India's oil marketing companies are set to increase the country's crude oil refining capacity by 35-40 million tonnes by fiscal 2030, reaching a total of 295 million tonnes, as per the CRISIL ratings. This expansion, driven by rising domestic oil consumption, will require an investment of Rs 1.9-2.2 lakh crore. Most additions will be brownfield expansions, reducing project risks and ensuring steady returns.

LTIMindtree strengthens partnership with Currys

LTIMindtree strengthened its partnership with Currys, a leading UK retailer of technology products and services, by enabling transformation of its omni-channel retail customer experiences leveraging Salesforce Service Cloud, Commerce Cloud and MuleSoft. This partnership was recognised with the Dreamforce Partner Innovation Award at Dreamforce 2024 in San Francisco, USA.

US FDA inspection at Biocon's API facility at Bengaluru

US Food and Drug Administration (US FDA) conducted a surveillance inspection of API facility (Site 2), at Bengaluru, Karnataka, between the 23rd to 27th September 2024. Four observations were cited at the end of the inspection, which the company will be addressing within the stipulated time.



US FDA inspection at Piramal Pharma's manufacturing facility at Ahmedabad

US FDA had inspected Piramal Pharma Limited's manufacturing facility at Ahmedabad, India and it has been concluded with Zero Form - 483 observations and No Action Indicated (NAI) designation. US FDA has issued an EIR for the said manufacturing facility.

Zydu Lifesciences received final approval from US FDA for Enzalutamide Capsules, 40 mg

Zydu Lifesciences Limited has received final approval from the United States Food and Drug Administration (US FDA) to manufacture Enzalutamide Capsules, 40 mg (USRLD: Xtandi Capsules, 40 mg). Enzalutamide capsules are androgen receptor inhibitors indicated for the treatment of patients with metastatic castration-resistant prostate cancer.

Enzalutamide Capsules will be produced at the Group's manufacturing site at Moraiya, Ahmedabad. Enzalutamide capsules, 40 mg had annual sales of US\$ 869 million in the United States (IQVIA MAT July 2024).

US FDA inspection at Lupin's manufacturing facility at Pithampur Unit-1

US FDA inspected Lupin's Pithampur Unit-1 API and finished product manufacturing facility from September 16 to September 27, 2024. The inspection closed with three observations each on the API and Finished Product side. Company is addressing the observations comprehensively and would respond to the US FDA within the stipulated timeframe.

Apollo Hospitals sells 16.9% stake in subsidiary Apollo Healthco for Rs 2,475 crore to Advent International

Apollo Hospitals Enterprise Ltd said that it has finalised a strategic agreement with Rasmeli Ltd, an affiliate of Advent International, to sell a 16.9% stake in its material subsidiary, Apollo Healthco Ltd (AHL).

The deal, valued at Rs 2,475 crore, will be executed in two tranches, reducing Apollo Hospitals' stake in Apollo Healthco from 94.91% to 78.88%, on a fully converted basis.

The deal also includes Apollo Healthco's acquisition of an 11.2% stake in Keimed from Shobana Kamineni, a promoter of Apollo Hospitals, for Rs 625.4 crore, along with an investment of Rs 99.99 crore into Keimed. Following this, Keimed will be amalgamated with Apollo Healthco.

US FDA completed inspection at Biocon Biologics' Insulin Facility at Johor Bahru, Malaysia

US Food and Drug Administration (US FDA) conducted a cGMP inspection at Biocon Biologics' Insulin Manufacturing Facility in Malaysia between September 17, and September 27, 2024. The inspection scope included a number of biologics manufacturing units comprising one (1) Drug Substance and one (1) Drug Product manufacturing units, one (1) Medical Device Assembly unit, one (1) Analytical Quality Control Laboratory, two (2) Microbiological Control Laboratories and two (2) Warehouses.

The inspection concluded with the issuance of a form 483 with observations broadly categorized as: five (5) observations across the Drug Substance and Drug Product facilities; zero (0) observations on the Medical Device Assembly unit; three (3) observations on the Analytical & Microbiological Quality Control Laboratory; and zero (0) observations on the Warehouse operations. There were no observations related to Data Integrity, Systemic Deficiencies or Quality Oversight at any of the units, noted by the agency, during the inspection.

Alembic Pharmaceuticals received EIR for its Oral Solid Formulation Facility (F-1) at Panelav

Company has received an Establishment Inspection Report (EIR) from the US FDA for the inspection carried out by them at Oral Solid Formulation Facility (F-I) from 17th July, 2024 to 26th July, 2024.

With this, for all the US FDA facilities of Alembic, EIRs are in place.

Gala Precision Engineering Q1FY25 result update

Revenue for the quarter grew 14.7% YoY at Rs 53.2 crore. EBITDA increased 27% YoY at Rs 10.85 crore. Net profit was up 40% YoY at Rs 6.3 crore.



Bajel Projects secured first Data Center order from an upcoming private service provider

Bajel Projects Limited announced its successful foray into the nascent data centre segment securing its first order from an upcoming data center service provider. Bajel has bagged an order for the design and construction of a 220/33 KV Gas Insulated Substation (GIS) Substation and transmission line extension for a colocation data center in Navi Mumbai. Bajel will leverage its extensive expertise in Design, Engineering, Procurement and Construction (EPC) to deliver critical power infrastructure solutions.

Dr. Reddy's Laboratories completes US\$ 620 million Investment in Switzerland Unit

Dr. Reddy's Laboratories Ltd. announced that it has completed a \$620 million investment in its Switzerland-based subsidiary, Dr. Reddy's Laboratories SA.

As part of the investment, DRL SA issued 6.2 million non-convertible preference shares, each with a nominal value of \$100, to the parent company on Sept. 27.

The fund infused by the company into Dr. Reddy's SA will be used for the acquisition of Nicotinell and related brands by way of acquisition of all of the quotas of Northstar Switzerland SARL incorporated in Switzerland owned by the Haleon Group.

Asian Energy Services secured Rs 82 crore contract from Oil India

Asian Energy Services Limited (AESL), has been awarded an order from Oil India for 2D Seismic Data Acquisition of 4,300 LKM in Rajasthan Basin under Mission Anveshan The total contract value is at ~Rs 82 crores inclusive of all taxes and duties including quoted GST and the order will be executed over a span of 18 months. The total order book as on date stands at approx. Rs 1,000 crore.

Important news/developments to influence markets

China's factory activity seen extending declines in Sept: Reuters poll

China's factory activity likely remained in contraction for the fifth consecutive month in September, due to weak domestic demand and rising global trade barriers. Reuters poll of 22 economists estimated the official purchasing managers' index (PMI) will come at 49.5, higher than August's reading of 49.1, but below the 50-point threshold that separates growth from contraction in activity.


US consumer spending resilient

U.S. consumer spending increased slightly less than expected in August. Consumer spending, which accounts for more than two-thirds of U.S. economic activity, rose 0.2% last month after an unrevised 0.5% gain in July, the Commerce Department's Bureau of Economic Analysis said. Economists polled by Reuters had forecast consumer spending climbing 0.3%.



Index	CMP	View	R1	R2	S1	S2
Nifty Oct Fut	26345.15	Bullish	26397	26449	26298	26251
BankNifty Oct Fut	54220.00	Bullish	54496	54772	54034	53848

Daily Technical View on Nifty



- Nifty snapped its six-session winning streak on Sept 27 after hitting its highest level of 26277.35 points.
- At close, Nifty was down 0.14% or 37.1 points at 26178.9.
- Cash market volumes on the NSE were up 36.2% compared to the previous day partly due to Nifty rebalancing volumes.
- Broad market indices ended marginally in the positive even as the advance decline ratio rose to 0.99:1.
- Nifty stayed in a 126 point range on Sept 27 and formed a small negative candle.
- After a series of upticks, Nifty seems to have taken a breather.
- Nifty could now face resistance from the 26250-26475 band on the upside, while 25849 could offer support in the near term.
- BankNifty has formed bearish “shooting star” candlestick pattern on the weekly chart. However, bearish implication of the same would be confirmed once it breaks the low of candle, which is placed at 53741 in spot.



OPEN SHORT TERM TRADING CALLS

NO.	RECO DT.	RECO	COMPANY NAME	ENTRY	CMP	SL	TARGET	UPSIDE %	VALID TILL
1	23-SEP-24	BUY	MANYAVAR	1310-1336.25	1,350.7	1,280.0	1403	3.9	7-OCT-24

OPEN E-MARGIN POSITIONAL CALLS

NO.	RECO DT.	RECO	COMPANY NAME	ENTRY	CMP	SL	TARGET 1	TARGET 2	UPSIDE %	VALID TILL
1	6-AUG-24	BUY	GREENPANEL*	358.60-343	383.0	358.6	390.0	439.0	15	6-NOV-24
2	13-AUG-24	BUY	VIJAYA DIAGONSTIC*	854.95-805	880.3	855.0	932.0	984.0	12	13-NOV-24
3	20-AUG-24	BUY	MASTEK	2828-2668	2641.5	2588.0	3087.0	3388.0	28	20-NOV-24
4	3-SEP-24	BUY	STAR HEALTH	636.35-603	615.0	587.0	690.0	732.0	19	3-DEC-24
5	10-SEP-24	BUY	POONAWALLA	388.95-373	395.8	363.0	424.0	455.0	15	10-NOV-24
6	13-SEP-24	BUY	LTF	170-177.70	187.9	163.0	192.0	207.0	10	13-NOV-24
7	16-SEP-24	BUY	ASTEC LIFESCIENCES	1229.65-1156	1181.1	1129.7	1370.0	1415.0	20	16-DEC-24
8	16-SEP-24	BUY	ACE*	1270-1294.15	1418.8	1294.2	1385.0	1470.0	4	16-DEC-24
9	18-SEP-24	BUY	ANGEL ONE	2627.50-2521	2532.3	2442.0	2867.0	3150.0	24	18-DEC-24
10	18-SEP-24	BUY	SOBHA*	1780-1831.30	1967.6	1831.3	1959.0	2150.0	9	18-DEC-24
11	18-SEP-24	BUY	CHEMPLAST	521.05-489	509.0	483.0	586.0	605.0	19	18-DEC-24
12	20-SEP-24	BUY	IDFC FIRST BANK	73.30-70.70	74.2	68.5	79.0	84.0	13	20-NOV-24
13	23-SEP-24	BUY	MAHARASHTRA BANK	60.06-57	59.8	55.5	65.0	71.0	19	23-DEC-24
14	23-SEP-24	BUY	UNION BANK	126.36-120	123.5	118.0	135.0	145.5	18	23-NOV-24
15	23-SEP-24	BUY	M&M FINANCE	331.10-318	333.5	312.0	352.0	375.0	12	23-NOV-24
16	25-SEP-24	BUY	CHAMBAL FERTILIZERS	510.60-492	525.3	478.0	549.0	580.0	10	25-NOV-24
17	26-SEP-24	BUY	TATA STEEL	156-162.70	166.6	150.0	175.0	188.0	13	26-NOV-24
18	26-SEP-24	BUY	SURYA ROSHNI	713.05-685	728.2	668.0	762.0	825.0	13	26-DEC-24
19	27-SEP-24	BUY	RENUKA SUGAR	50.67-48.25	53.1	46.8	56.0	61.0	15	27-DEC-24

*= 1st Target Achieved



OPEN FUNDAMENTAL CALLS

Time Horizon= 2 - 3 Quarters

NO.	COMPANY NAME	RECO DATE	CMP	BUYING RANGE	TARGET 1	TARGET 2	UPSIDE %
1	MANYAVAR*	23-Oct-23	1350.7	1300-1325	1445	1555	15.13
2	JYOTIRES	16-Nov-23	1543	1621-1650	1806	1936	25.47
3	JTLIND	11-Jan-24	229.3	252-261	278.75	300.5	31.05
4	JAYBARMARU	23-Jan-24	102.11	134-137	150	161	57.67
5	SHREDIGCEM	23-Jan-24	95.16	116-120	129	144.5	51.85
6	SATIN	29-Jan-24	196.33	251-257	279	303	54.33
7	NH	5-Feb-24	1204.25	1342-1358	1467	1557	29.29
8	CYIENTDLM*	12-Feb-24	672.4	768-784	845	905	34.59
9	BIRLACORPN	27-Feb-24	1236.25	1725-1760	1891	1996	61.46
10	CRISIL	4-Mar-24	4559.95	4900-5000	5414	5821	27.65
11	CYIENT	3-Apr-24	1901.85	1989-2029	2191	2340	23.04
12	MAHLIFE	22-Apr-24	542.65	615-625	684	725	33.60
13	UBL	29-Apr-24	2180.9	2030-2050	2245	2401	10.09
14	ALLSEC*	21-May-24	1051.45	1043-1065	1162	1261	19.93
15	MAHINDCIE*	24-May-24	544.3	536-548	588	629	15.56
16	MMFL*	27-May-24	583.35	1120-1145	620	672	15.20
17	JKIL*	18-Jun-24	777.6	813-829	902	976	25.51
18	INDNIPPON*	18-Jun-24	765.3	785-800	863	932	21.78
19	LUMAXTECH	26-Jun-24	572.55	550-560	615	648	13.18
20	ITDCEM*	1-Jul-24	543.15	520-530	579	626	15.25
21	BALMLAWRIE*	5-Jul-24	274.2	268-274	300	320	16.70
22	BSOFT	8-Jul-24	604.05	705-725	785	845	39.89
23	KPIL*	8-Jul-24	1407.55	1216-1240	1346	1461	3.80
24	ZENSARTECH	15-Jul-24	676.7	760-780	843	905	33.74
25	GODREJAGRO	15-Jul-24	774.25	826-840	909	978	26.32
26	TALBROAUTO*	22-Jul-24	333.95	346-354	387	417	24.87
27	GRANULES*	5-Aug-24	556.1	644-653	706	758	36.31
28	INDIAGLYCO*	12-Aug-24	1227.5	1208-1226	1338	1430.5	16.54
29	EMAMILTD	12-Aug-24	751.65	795-805	870	927	23.33
30	CIPLA	19-Aug-24	1672.5	1573-1587	1721	1819	8.76
31	DODLA	19-Aug-24	1183.4	1179-1194	1305.5	1387	17.20
32	EPL	26-Aug-24	255.05	245-255	274	292	14.49
33	ELECTCAST	26-Aug-24	215.64	216-220	241.5	257	19.18

*= 1st Target Achieved



OPEN FUNDAMENTAL CALLS

Time Horizon= 2 - 3 Quarters

NO.	COMPANY NAME	RECO DATE	CMP	BUYING RANGE	TARGET 1	TARGET 2	UPSIDE %
34	FORTIS*	26-AUG-24	596.7	549-558	607	646	8.26
35	LGBBROSLTD*	2-SEP-24	1361.45	1365-1395	1519	1620	18.99
36	PATANJALI	2-SEP-24	1701.5	1930-1960	2124	2295	34.88
37	SUPRIYA*	9-SEP-24	564.1	590-603	653.5	706.5	25.24
38	FIEMIND	9-SEP-24	1717.45	1610-1645	1778	1915	11.50
39	BHARTIARTL	16-SEP-24	1734.6	1618-1650	1785	1897	9.36
40	POKARNA	16-SEP-24	1037.05	1069-1092	1182	1260.5	21.55
41	IEX	23-SEP-24	206.25	229-234	253	273.5	32.61
42	ACE	23-SEP-24	1418.8	1384-1412	1537	1632	15.03
43	MGL	23-SEP-24	1946.6	1885-1925	2080	2245	15.33
44	HERITGFOOD	23-SEP-24	633.05	588-614	655	707	11.68

*= 1st Target Achieved



Disclaimer:

This report has been prepared by HDFC Securities Ltd and is solely for information of the recipient only. The report must not be used as a singular basis of any investment decision. The views herein are of a general nature and do not consider the risk appetite or the particular circumstances of an individual investor; readers are requested to take professional advice before investing. Nothing in this document should be construed as investment advice. Each recipient of this document should make such investigations as they deem necessary to arrive at an independent evaluation of an investment in securities of the companies referred to in this document (including merits and risks) and should consult their own advisors to determine merits and risks of such investment. The information and opinions contained herein have been compiled or arrived at, based upon information obtained in good faith from sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. Descriptions of any company or companies or their securities mentioned herein are not intended to be complete. HSL is not obliged to update this report for such changes. HSL has the right to make changes and modifications at any time.

This report is not directed to, or intended for display, downloading, printing, reproducing or for distribution to or use by, any person or entity who is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject HSL or its affiliates to any registration or licensing requirement within such jurisdiction.

If this report is inadvertently sent or has reached any person in such country, especially, United States of America, the same should be ignored and brought to the attention of the sender. This document may not be reproduced, distributed or published in whole or in part, directly or indirectly, for any purposes or in any manner.

Foreign currencies denominated securities, wherever mentioned, are subject to exchange rate fluctuations, which could have an adverse effect on their value or price, or the income derived from them. In addition, investors in securities such as ADRs, the values of which are influenced by foreign currencies effectively assume currency risk. It should not be considered to be taken as an offer to sell or a solicitation to buy any security.

This document is not, and should not, be construed as an offer or solicitation of an offer, to buy or sell any securities or other financial instruments. This report should not be construed as an invitation or solicitation to do business with HSL. HSL may from time to time solicit from, or perform broking, or other services for, any company mentioned in this mail and/or its attachments.

HSL and its affiliated company(ies), their directors and employees may; (a) from time to time, have a long or short position in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

HSL, its directors, analysts or employees do not take any responsibility, financial or otherwise, of the losses or the damages sustained due to the investments made or any action taken on basis of this report, including but not restricted to, fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc.

HSL and other group companies, its directors, associates, employees may have various positions in any of the stocks, securities and financial instruments dealt in the report, or may make sell or purchase or other deals in these securities from time to time or may deal in other securities of the companies / organizations described in this report. As regards the associates of HSL please refer the website.

HSL or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

HSL or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction in the normal course of business.



HSL or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither HSL nor Research Analysts have any material conflict of interest at the time of publication of this report. Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. HSL may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report. Research entity has not been engaged in market making activity for the subject company. Research analyst has not served as an officer, director or employee of the subject company. We have not received any compensation/benefits from the subject company or third party in connection with the Research Report.

Please note that HDFC Securities has a proprietary trading desk. This desk maintains an arm's length distance with the Research team and all its activities are segregated from Research activities. The proprietary desk operates independently, potentially leading to investment decisions that may deviate from research views.

HDFC securities Limited, I Think Techno Campus, Building - B, "Alpha", Office Floor 8, Near Kanjurmarg Station, Opp. Crompton Greaves, Kanjurmarg (East), Mumbai 400 042 Phone: (022) 3075 3400 Fax: (022) 2496 5066

Compliance Officer: Murli V Karkera Email: complianceofficer@hdfcsec.com Phone: (022) 3045 3600

For grievance redressal contact Customer Care Team Email: customercare@hdfcsec.com Phone: (022) 3901 9400

HDFC Securities Limited, SEBI Reg. No.: NSE, BSE, MSEI, MCX: INZ000186937; AMFI Reg. No. ARN: 13549; PFRDA Reg. No. POP: 11092018; IRDA Corporate Agent License No.: CA0062; SEBI Research Analyst Reg. No.: INH000002475; SEBI Investment Adviser Reg. No.: INA000011538; CIN - U67120MH2000PLC152193

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Mutual Funds Investments are subject to market risk. Please read the offer and scheme related documents carefully before investing.

Registration granted by SEBI, membership of BASL (in case of IAs) and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.